Amyloidosis - secondary systemic; AA amyloidosis
Secondary systemic amyloidosis is a disorder in which abnormal proteins build up in tissues and organs. Clumps of the abnormal proteins are called amyloid deposits.
Secondary means it occurs because of another disease or situation. For example, this condition usually occurs due to long-term (chronic) infection or inflammation. In contrast, primary amyloidosis means there is no other disease that is causing the condition.
Systemic means that the disease affects the entire body.
The exact cause of secondary systemic amyloidosis is unknown. You are more likely to develop secondary systemic amyloidosis if you have a long-term infection or inflammation.
This condition may occur with:
Symptoms of secondary systemic amyloidosis depend on which body tissue is affected by the protein deposits. These deposits damage normal tissues. This may lead to the symptoms or signs of this illness, including:
The health care provider will perform a physical examination and ask about your symptoms.
Tests that may be done include:
The condition that is causing the amyloidosis should be treated. In some cases, the drug colchicine or an immunosuppressive drug (medicine that suppresses the immune system) is prescribed.
How well a person does depends on which organs are affected. It also depends on, whether the disease that is causing it can be controlled. If the disease involves the heart and kidneys, it may lead to organ failure and death.
Health problems that may result from secondary systemic amyloidosis include:
Contact your provider if you have symptoms of this condition. The following are serious symptoms that need prompt medical attention:
If you have a disease that is known to increase your risk for this condition, make sure you get it treated. This may help prevent amyloidosis.
Gertz MA. Amyloidosis. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 179.
Papa R, Lachmann HJ. Secondary, AA, amyloidosis. Rheum Dis Clin North Am. 2018;44(4):585-603. PMID: 30274625 pubmed.ncbi.nlm.nih.gov/30274625/.BACK TO TOP
Review Date: 4/18/2023
Reviewed By: John Roberts, MD, Professor of Internal Medicine (Medical Oncology), Yale Cancer Center, New Haven, CT. He is board certified in Internal Medicine, Medical Oncology, Pediatrics, Hospice and Palliative Medicine. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
Health Content Provider
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2024 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.